Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

overactive bladder

This page shows the latest overactive bladder news and features for those working in and with pharma, biotech and healthcare.

Urovant slips on phase 3 incontinence drug data

Urovant slips on phase 3 incontinence drug data

The phase 3 EMPOWUR trial of vibegron in patients with incontinence caused by overactive bladder (OAB) showed that the beta-3 adrenergic agonist performed significantly better than placebo on the two

Latest news

More from news
Approximately 4 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new

  • Allergan and taking a specialised approach Allergan and taking a specialised approach

    In addition to migraine and adult spasticity, its approved indications include overactive bladder, muscle stiffness in elbow, wrist and fingers, muscle problems in the eye, crow's feet lines and severe

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice

  • Show stopper exposes taboo

    As part of a national campaign called A Matter of Urgency’, the show-stopping garden was designed to raise awareness of Overactive Bladder which affects nearly one in five people in ... Nearly one in five people in the UK over 40 have an overactive

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • emotive boosts health economics and outcomes research team

    His MSc project involved performing a health economic evaluation of the cost-effectiveness of different overactive bladder treatments available in the UK. ... The appointment of Trishal, with his specific expertise in visual science and overactive bladder

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Quick links

Infographics

Multimedia